Company news

BioAtla, Inc. news in 2025

BioAtla, Inc.'s news releases, calls and decks from 2025, newest first.

View company

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

December 31, 2025

BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

November 21, 2025

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

November 13, 2025

BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

November 7, 2025

BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

November 5, 2025

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

October 23, 2025

BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

October 19, 2025

BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025

October 3, 2025

BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA

September 8, 2025

BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

August 7, 2025

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

August 4, 2025

BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting

July 17, 2025

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

July 3, 2025

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen

June 2, 2025

BioAtla: Earnings Release (bioatla reports first quarter 2025 financial results and)

May 7, 2025

BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

May 6, 2025

BioAtla to Participate in the Citizens Life Sciences Conference

April 30, 2025

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

April 29, 2025

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

April 24, 2025

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

April 23, 2025

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

March 27, 2025

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

March 20, 2025

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

March 19, 2025

Calls in 2025

Decks in 2025